S.C. Ropharma Balance Sheet Health
Financial Health criteria checks 6/6
S.C. Ropharma has a total shareholder equity of RON253.0M and total debt of RON68.1M, which brings its debt-to-equity ratio to 26.9%. Its total assets and total liabilities are RON885.3M and RON632.4M respectively. S.C. Ropharma's EBIT is RON21.1M making its interest coverage ratio 3.6. It has cash and short-term investments of RON32.5M.
Key information
26.9%
Debt to equity ratio
RON 68.09m
Debt
| Interest coverage ratio | 3.6x |
| Cash | RON 32.48m |
| Equity | RON 252.99m |
| Total liabilities | RON 632.36m |
| Total assets | RON 885.35m |
Recent financial health updates
Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?
Jun 01
S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt
May 15Recent updates
S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital
Dec 06Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital
Dec 09S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return
Sep 23Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?
Jun 01Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital
Mar 16S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt
May 15S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively
Mar 26Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?
Dec 23
We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide
Nov 24Financial Position Analysis
Short Term Liabilities: RPH's short term assets (RON526.5M) exceed its short term liabilities (RON520.1M).
Long Term Liabilities: RPH's short term assets (RON526.5M) exceed its long term liabilities (RON112.3M).
Debt to Equity History and Analysis
Debt Level: RPH's net debt to equity ratio (14.1%) is considered satisfactory.
Reducing Debt: RPH's debt to equity ratio has reduced from 40.3% to 26.9% over the past 5 years.
Debt Coverage: RPH's debt is well covered by operating cash flow (66.1%).
Interest Coverage: RPH's interest payments on its debt are well covered by EBIT (3.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:57 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
S.C. Ropharma S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Roxana Dascalu | SSIF IEBA Trust SA |